Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?

ABSTRACT

The rapid development of new and selective anticoagulant agents has triggered the question of which activated coagulation factor would be a better target for the inhibition of coagulation. Indirect comparisons between studies on the different drugs are problematic due to the plethora of characteristics that may differ between them. Even head-to-head comparisons in the same study may not determine the optimal target due to differences in pharmacokinetics between the agents. Therefore, the answer to this question relies on theoretical speculations based on knowledge of some of the factors that seem to have an influence on efficacy and safety. Ultimately, drugs with equal pharmacokinetic characteristics that are administered in equipotent doses may have a similar global effect on coagulation, independent of the inhibitory mechanism. Conversely, the differentiated inhibition of the coagulation protease on vascular receptors may play a greater role for effects that are not traditionally considered as part of hemostasis.

KEYWORDS

Factor Xa inhibitor - hemorrhage - thrombin inhibitor - thrombosis - vascular receptors

REFERENCES

• 1 Carlsson S, Adler G, Elg M. The antithrombotic effects of the oral, direct thrombin inhibitor H 376/95 and other anticoagulants tested in a deep venous thrombus conscious rat model.  Haemostasis . 2000;  30 (suppl 1) 166
• 2 Boström S L, Sarich T C. Effects of melagatran, the active form of the oral, direct thrombin inhibitor H 376/95, and dalteparin, on the endogenous thrombin potential in venous blood from healthy male subjects.  Haemostasis . 2000;  30 (suppl 1) 22
• 3 Wolzt M, Boström S L, Wollbratt M. et al . Ximelagatran, an oral direct thrombin inhibitor, normalizes platelet activation and inhibits thrombin generation in patients with non-valvular atrial fibrillation [abstract 263].  Pharmacotherapy . 2002;  22 1365
• 4 Eriksson U G, Fager G, Eriksson L M. et al . Effect of acetylsalicylic acid on the pharmacodynamics and pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95).  Clin Pharmacol Ther . 2001;  69 24
• 5 Berntsson P, Mattsson C, Johansson T, Strömqvist M. Enhancement of fibrinolysis by melagatran via inhibition of thrombin-induced activation of pro-CPU (TAFI) [abstract].  Thromb Haemost . 2001;  86(suppl) P2014
• 6 Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin.  Circulation . 2000;  103 1479-1484
• 7 Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial.  Lancet . 1999;  353 429-438
• 8 Bittl J A, Strony J, Brinker J A. et al . Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.  N Engl J Med . 1995;  333 764-769
• 9 Bittl J A, Chaitman B R, Feit F, Kimball W, Topol E J. Bivalirudin versus heparin during coronary angiography for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study.  Am Heart J . 2001;  142 952-959
• 10 Gustafsson D, Antonsson T, Bylund R. et al . Effects of melagatran, a new low-molecular-weight thrombin inhibitor on thrombin and fibrinolytic enzymes.  Thromb Haemost . 1998;  79 110-118
• 11 Klement P, Carlsson S, Rak J. et al . The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.  J Thromb Haemost . 2003;  1 587-594
• 12 Eriksson U G, Bredberg U, Gislén K. et al . Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects.  Eur J Clin Pharmacol . 2003;  59 35-43